Elicio Therapeutics (ELTX) Operating Leases (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Operating Leases came in at $3.8 million in Q1 2026, down 21.42% YoY from $4.9 million in Q1 2025, and down 6.62% on a QoQ basis from $4.1 million in Q4 2025.
Elicio Therapeutics (ELTX) Operating Leases (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Operating Leases data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Operating Leases fell 21.42% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 21.42% YoY) and the FY2025 annual result came in at $4.1 million, down 19.8% from the prior year.
- Operating Leases slipped to $3.8 million in Q1 2026, from $4.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $6.8 million in Q4 2022 to a low of $70000.0 in Q1 2023.
- A 5-year average of $4.9 million and a median of $5.1 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases sank 97.84% — and 2024, when it jumped 8172.86%.
- Tracing ELTX's Operating Leases over 5 years: stood at $6.8 million in 2022, then dropped by 11.52% to $6.0 million in 2023, then declined by 15.02% to $5.1 million in 2024, then retreated by 19.8% to $4.1 million in 2025, then decreased by 6.62% to $3.8 million in 2026.
- The last three Operating Leases figures came in at $3.8 million (Q1 2026), $4.1 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.61 Mn |
| Mar 31, 2026 | 3.82 Mn |
| Dec 31, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Jun 30, 2025 | 5.57 Mn |
| Mar 31, 2025 | 4.87 Mn |
| Dec 31, 2024 | 5.11 Mn |
| Sep 30, 2024 | 6.22 Mn |
| Jun 30, 2024 | 6.42 Mn |
| Mar 31, 2024 | 5.79 Mn |
| Dec 31, 2023 | 6.01 Mn |
| Sep 30, 2023 | 6.22 Mn |
| Jun 30, 2023 | 6.42 Mn |
| Mar 31, 2023 | 70,000.00 |
| Dec 31, 2022 | 6.79 Mn |
| Sep 30, 2022 | 3.71 Mn |
| Jun 30, 2022 | 3.93 Mn |
| Mar 31, 2022 | 3.24 Mn |
| Dec 31, 2021 | 3.48 Mn |
| Sep 30, 2021 | 3.71 Mn |